Prospects for combined use of oncolytic viruses and CAR T-cells

Adam Ajina, John Maher*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

83 Citations (Scopus)
678 Downloads (Pure)


With the approval of talimogene laherparepvec (T-VEC) for inoperable locally advanced or metastatic malignant melanoma in the USA and Europe, oncolytic virotherapy is now emerging as a viable therapeutic option for cancer patients. In parallel, following the favourable results of several clinical trials, adoptive cell transfer using chimeric antigen receptor (CAR)-redirected T-cells is anticipated to enter routine clinical practice for the management of chemotherapy-refractory B-cell malignancies. However, CAR T-cell therapy for patients with advanced solid tumours has proved far less successful. This Review draws upon recent advances in the design of novel oncolytic viruses and CAR T-cells and provides a comprehensive overview of the synergistic potential of combination oncolytic virotherapy with CAR T-cell adoptive cell transfer for the management of solid tumours, drawing particular attention to the methods by which recombinant oncolytic viruses may augment CAR T-cell trafficking into the tumour microenvironment, mitigate or reverse local immunosuppression and enhance CAR T-cell effector function and persistence.

Original languageEnglish
Article number90
Number of pages27
JournalJournal for ImmunoTherapy of Cancer
Issue number1
Early online date21 Nov 2017
Publication statusE-pub ahead of print - 21 Nov 2017


  • Adoptive cell transfer
  • CAR T-cell
  • Chimeric antigen receptor
  • Combination strategies
  • Oncolytic virus
  • Solid tumours
  • Synergism


Dive into the research topics of 'Prospects for combined use of oncolytic viruses and CAR T-cells'. Together they form a unique fingerprint.

Cite this